1. Home
  2. VLN vs DSGN Comparison

VLN vs DSGN Comparison

Compare VLN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VLN
  • DSGN
  • Stock Information
  • Founded
  • VLN 2006
  • DSGN 2017
  • Country
  • VLN Israel
  • DSGN United States
  • Employees
  • VLN N/A
  • DSGN N/A
  • Industry
  • VLN Semiconductors
  • DSGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • VLN Technology
  • DSGN Health Care
  • Exchange
  • VLN Nasdaq
  • DSGN Nasdaq
  • Market Cap
  • VLN 236.8M
  • DSGN 208.9M
  • IPO Year
  • VLN N/A
  • DSGN 2021
  • Fundamental
  • Price
  • VLN $2.65
  • DSGN $3.67
  • Analyst Decision
  • VLN Strong Buy
  • DSGN Hold
  • Analyst Count
  • VLN 1
  • DSGN 1
  • Target Price
  • VLN $4.00
  • DSGN $4.00
  • AVG Volume (30 Days)
  • VLN 394.7K
  • DSGN 89.5K
  • Earning Date
  • VLN 08-06-2025
  • DSGN 08-04-2025
  • Dividend Yield
  • VLN N/A
  • DSGN N/A
  • EPS Growth
  • VLN N/A
  • DSGN N/A
  • EPS
  • VLN N/A
  • DSGN N/A
  • Revenue
  • VLN $63,128,000.00
  • DSGN N/A
  • Revenue This Year
  • VLN $25.99
  • DSGN N/A
  • Revenue Next Year
  • VLN $17.25
  • DSGN N/A
  • P/E Ratio
  • VLN N/A
  • DSGN N/A
  • Revenue Growth
  • VLN N/A
  • DSGN N/A
  • 52 Week Low
  • VLN $1.67
  • DSGN $2.60
  • 52 Week High
  • VLN $3.50
  • DSGN $7.77
  • Technical
  • Relative Strength Index (RSI)
  • VLN 67.50
  • DSGN 48.40
  • Support Level
  • VLN $2.07
  • DSGN $3.65
  • Resistance Level
  • VLN $2.73
  • DSGN $4.21
  • Average True Range (ATR)
  • VLN 0.15
  • DSGN 0.23
  • MACD
  • VLN 0.06
  • DSGN -0.00
  • Stochastic Oscillator
  • VLN 92.57
  • DSGN 23.81

About VLN Valens Semiconductor Ltd.

Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: